# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phas...
Needham analyst Ami Fadia initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Pric...
Guggenheim analyst Yatin Suneja initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announce...
Truist Securities analyst Joon Lee maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $150 price tar...